FDA
-
-
-
-
-
-
-
Piper Sandler Downgrades Capricor Therapeutics (CAPR) to Neutral
-
-
-
-
-
-
-
Capricor disputes FDA briefing materials ahead of deramiocel review
-
-
-
-
-
-
-
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
-
-
-
-
-
-
-
FDA sets new PDUFA date for Capricor's Deramiocel therapy
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Raised to $54 at Oppenheimer
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

